Literature DB >> 12001695

Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.

Sigal Korem1, Zaki Kraiem, Eitan Shiloni, Oved Yehezkel, Orit Sadeh, Murray B Resnick.   

Abstract

BACKGROUND: Matrix metalloproteinases are proteolytic enzymes that degrade extracellular matrix components. Numerous studies have demonstrated that individual MMPs play a crucial role in tumor invasion and metastasis.
OBJECTIVE: To examine the expression of MMPs and their inhibitor TIMP-2 in neoplastic and normal thyroid tissues.
METHODS: We examined 33 cases of thyroid tumor (papillary, follicular and medullary carcinoma, follicular adenoma and multinodular goiter). MMP protein content and activity were measured by enzyme-linked immunosorbent assay and gel zymography. Immunohistochemistry was also performed.
RESULTS: The thyroid tissues examined secreted MMP-2 and 9 as well as TIMP-2, but only MMP-2 was significantly higher in papillary carcinoma cases compared to the adjacent normal tissue or to the other tumor entities. Increased MMP-2 immunohistochemical staining was demonstrated in the neoplastic papillary epithelial component. No significant difference was seen between papillary carcinomas with lymph node metastases and those without.
CONCLUSIONS: Increased MMP-2 expression may be useful as a diagnostic marker to differentiate papillary carcinoma from other thyroid neoplasms, but it cannot serve as a useful prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001695

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  5 in total

1.  Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line.

Authors:  Szu-Tah Chen; Dah-Wel Liu; Jen-Der Lin; Fang-Wu Chen; Yu-Yao Huang; Brend Ray-Sea Hsu
Journal:  Clin Exp Metastasis       Date:  2011-11-01       Impact factor: 5.150

2.  Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.

Authors:  Amr Ahmed El Badry; Amal Abou El-Fadle; Abdel Latif El-Balshy
Journal:  MedGenMed       Date:  2007-07-03

3.  Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.

Authors:  Leandro Lacerda; Ana Paula de Faria; Vanessa Fontana; Heitor Moreno; Valéria Sandrim
Journal:  Arq Bras Cardiol       Date:  2015-06-02       Impact factor: 2.000

4.  Reduced tissue inhibitor of metalloproteinase-2 expression is associated with advanced medullary thyroid carcinoma.

Authors:  Simone Magagnin Wajner; Clarissa Capp; Beatriz Assis Brasil; Luise Meurer; Ana Luiza Maia
Journal:  Oncol Lett       Date:  2013-12-19       Impact factor: 2.967

5.  Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration.

Authors:  Ilona Marecko; Dubravka Cvejic; Sonja Selemetjev; Svetlana Paskas; Svetislav Tatic; Ivan Paunovic; Svetlana Savin
Journal:  Croat Med J       Date:  2014-04       Impact factor: 1.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.